Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/36054
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | MATTOS, Cristiana de | |
dc.contributor.author | KIM, Hyoun S. | |
dc.contributor.author | MARASALDI, Renata F. | |
dc.contributor.author | REQUIAO, Marinalva G. | |
dc.contributor.author | OLIVEIRA, Elen Cristina de | |
dc.contributor.author | FILOMENSKY, Tatiana | |
dc.contributor.author | TAVARES, Hermano | |
dc.date.accessioned | 2020-06-01T14:57:30Z | |
dc.date.available | 2020-06-01T14:57:30Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.40, n.2, p.186-190, 2020 | |
dc.identifier.issn | 0271-0749 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/36054 | |
dc.description.abstract | Background Topiramate is an anticonvulsant that has shown promise as a pharmacological agent for the treatment of addictive disorders, including compulsive buying disorder (CBD). The aim of the present study was to examine the efficacy of topiramate in the treatment of CBD and its associated characteristics using a 12-week randomized, double-blind, placebo-controlled design. Methods Fifty patients seeking treatment of CBD who met the inclusion criteria were randomly assigned to either the experimental group (n = 25) or the control group (n = 25). Both groups received 4 sessions of psychoeducation. Results Forty-four participants completed the follow-up with no differences in the rate of dropout between groups. There were no differences between participants who received topiramate or placebo in reducing CBD symptoms assessed by the primary outcome scale (Yale-Brown Obsessive-Compulsive Scale - Shopping Version). However, participants who received topiramate were significantly more likely to show clinical improvement when assessed by a secondary outcome measure, the Compulsive Buying Follow-Up Scale. In addition, there was a trend among participants who received topiramate to report improvements in aspects of hoarding and impulsivity compared with the control group. There were significant improvements in comorbid depression and social adjustments over time, but no group x time interaction was found. Conclusions The results do not provide support for the use of topiramate in the treatment of CBD. Future investigation with larger and representative samples and longer follow-up period are needed. | eng |
dc.description.sponsorship | Brazilian National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq) [445465/2014-0] | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.relation.ispartof | Journal of Clinical Psychopharmacology | |
dc.rights | restrictedAccess | eng |
dc.subject | compulsive buying disorder | eng |
dc.subject | clinical trial | eng |
dc.subject | double blind | eng |
dc.subject | placebo controlled | eng |
dc.subject | topiramate | eng |
dc.subject.other | cognitive-behavioral therapy | eng |
dc.subject.other | portuguese version | eng |
dc.subject.other | scale | eng |
dc.subject.other | reliability | eng |
dc.subject.other | validation | eng |
dc.subject.other | inventory | eng |
dc.subject.other | validity | eng |
dc.title | A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disorder | eng |
dc.type | article | eng |
dc.rights.holder | Copyright LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.identifier.doi | 10.1097/JCP.0000000000001183 | |
dc.identifier.pmid | 32134854 | |
dc.subject.wos | Pharmacology & Pharmacy | eng |
dc.subject.wos | Psychiatry | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | KIM, Hyoun S.:Univ Calgary, Addict Behav Lab, Dept Psychol, Calgary, AB, Canada | |
hcfmusp.description.beginpage | 186 | |
hcfmusp.description.endpage | 190 | |
hcfmusp.description.issue | 2 | |
hcfmusp.description.volume | 40 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000526401500012 | |
hcfmusp.origem.id | 2-s2.0-85081530604 | |
hcfmusp.publisher.city | PHILADELPHIA | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Amorim Patricia, 2000, Revista Brasileira de Psiquiatria, V22, P106 | eng |
hcfmusp.relation.reference | BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5 | eng |
hcfmusp.relation.reference | Berlin HA, 2013, WORLD J BIOL PSYCHIA, V14, P121, DOI 10.3109/15622975.2011.560964 | eng |
hcfmusp.relation.reference | Black DW, 2001, CNS DRUGS, V15, P17, DOI 10.2165/00023210-200115010-00003 | eng |
hcfmusp.relation.reference | Bullock K, 2003, DRUG TODAY, V39, P695, DOI 10.1358/dot.2003.39.9.799477 | eng |
hcfmusp.relation.reference | de Brito AMC, 2017, J GAMBL STUD, V33, P249, DOI 10.1007/s10899-016-9620-z | eng |
hcfmusp.relation.reference | Chow S, 2008, SAMPLE SIZE CALCULAT, P89 | eng |
hcfmusp.relation.reference | Claudino AM, 2007, J CLIN PSYCHIAT, V68, P1324, DOI 10.4088/JCP.v68n0901 | eng |
hcfmusp.relation.reference | David V, 1998, EUR J NEUROSCI, V10, P1394, DOI 10.1046/j.1460-9568.1998.00150.x | eng |
hcfmusp.relation.reference | de Mattos CN, 2019, PSYCHIAT RES, V282, DOI 10.1016/j.psychres.2018.12.078 | eng |
hcfmusp.relation.reference | Filomensky TZ, 2012, COMPR PSYCHIAT, V53, P554, DOI 10.1016/j.comppsych.2011.09.005 | eng |
hcfmusp.relation.reference | First M, 1997, STRUCTURED CLIN INTE | eng |
hcfmusp.relation.reference | Fontenelle IS, 2010, PSYCHOL REP, V106, P279, DOI 10.2466/PR0.106.1.279-296 | eng |
hcfmusp.relation.reference | Gorenstein C, 2002, J AFFECT DISORDERS, V69, P167, DOI 10.1016/S0165-0327(01)00300-7 | eng |
hcfmusp.relation.reference | Grant JE, 2016, JAMA PSYCHIAT, V73, P490, DOI 10.1001/jamapsychiatry.2016.0060 | eng |
hcfmusp.relation.reference | Guy W, 1976, ECDEU ASSESSMENT MAN, P76 | eng |
hcfmusp.relation.reference | Hague B, 2016, J BEHAV ADDICT, V5, P379, DOI 10.1556/2006.5.2016.064 | eng |
hcfmusp.relation.reference | Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3 | eng |
hcfmusp.relation.reference | Johnson BA, 2013, ADDICT BIOL, V18, P405, DOI 10.1111/j.1369-1600.2012.00499.x | eng |
hcfmusp.relation.reference | Leite PL, 2014, COMPR PSYCHIAT, V55, P1462, DOI 10.1016/j.comppsych.2014.04.012 | eng |
hcfmusp.relation.reference | Leite Priscilla Lourenço, 2011, J. bras. psiquiatr., V60, P176, DOI 10.1590/S0047-20852011000300005 | eng |
hcfmusp.relation.reference | Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1 | eng |
hcfmusp.relation.reference | Malloy-Diniz LF, 2015, REV BRAS PSIQUIATR, V37, P245, DOI 10.1590/1516-4446-2014-1599 | eng |
hcfmusp.relation.reference | Mitchell JE, 2006, BEHAV RES THER, V44, P1859, DOI 10.1016/j.brat.2005.12.009 | eng |
hcfmusp.relation.reference | Mueller A, 2007, BEHAV RES THER, V45, P2754, DOI 10.1016/j.brat.2007.07.012 | eng |
hcfmusp.relation.reference | Porter Roger J, 2012, Handb Clin Neurol, V108, P663, DOI 10.1016/B978-0-444-52899-5.00021-6 | eng |
hcfmusp.relation.reference | Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi | eng |
hcfmusp.relation.reference | Soares C, 2016, CNS DRUGS, V30, P281, DOI 10.1007/s40263-016-0324-9 | eng |
hcfmusp.relation.reference | Toledo EL, 2015, J CLIN PSYCHIAT, V76, P447, DOI 10.4088/JCP.13m08964 | eng |
hcfmusp.relation.reference | World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1533-712X | |
hcfmusp.citation.scopus | 6 | |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MPS Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/23 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.